Life sciences consulting company Aptiv Solutions announced that it acquired Medical Device Consultants Inc., broadening its reach in medical device regulation and strategy.
North Attleboro, Mass.-based regulatory consulting and clinical research organization MDCI has been around since 1980, offering regulatory and clinical services to the med-tech sector.
"We look forward to leveraging the unique expertise of MDCI’s thirty-year success, with our existing portfolio of device and diagnostic consulting offerings, across a broad array of therapeutic areas," Aptiv chairman & CEO Patrick Donnelly said in prepared remarks. "We are delighted to welcome the seasoned group of medical device and diagnostic experts from MDCI to the company, as we continue to broaden our acumen in medical device and adaptive trial methodology.”
Aptiv offers biopharmaceutical and med-tech development services, including clinical trial design and execution and medical device consulting and trial execution. The merger allows the Reston, Va.-based company to offer a greater depth of services in the medical device arena.
"The increased rigor demanded by regulatory agencies around the world for medical device development and approvals requires the expertise and scale of a global service provider with focus on the unique aspects of medical devices," according to a press release.
The terms of the merger were not disclosed.
Here’s a roundup of companies announcing mergers, acquisitions and divestitures.
- Bayer puts down $125 for blood vessel clearing company
Medrad Inc., a division of Bayer Healthcare (ETR:BAYN), is prepared to put down $125 million for Kirkland, Wash.-based Pathway Medical Technologies Inc., maker of a device that clears blood vessel blockages in the legs, Xconomy reported. The deal hasn’t been announced publicly and is pending a green light from regulators and shareholders.
- IVD closes seals the deal on $2 billion Immucor acquisition
TPG Capital affiliate IVD Holdings closed the deal on the $2 billion acquisition of Norcross, Ga.-based blood diagnostics company Immucor Inc. (NSDQ:BLUD), a deal first announced early in July. TPG paid $27 per share in cash, a 30 percent premium over share price prior to the public announcement of the acquisition .